191 related articles for article (PubMed ID: 28000102)
1. Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn-Research-Confirm Process.
Liu D; Zhang Y; Jiang J; Choi J; Li X; Zhu D; Xiao D; Ding Y; Fan H; Chen L; Hu P
Clin Pharmacokinet; 2017 Aug; 56(8):925-939. PubMed ID: 28000102
[TBL] [Abstract][Full Text] [Related]
2. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetic/Pharmacodynamic Analysis of the Glucokinase Activator PB201 in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus: Facilitating the Clinical Development of PB201 in China.
Song L; Cao F; Niu S; Xu M; Liang R; Ding K; Lin Z; Yao X; Liu D
Clin Pharmacokinet; 2024 Jan; 63(1):93-108. PubMed ID: 37985591
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.
Morrow LA; Leonsson-Zachrisson M; Ericsson H; Wollbratt M; Knutsson M; Hompesch M; Norjavaara E
Diabetes Obes Metab; 2012 Dec; 14(12):1114-22. PubMed ID: 22775976
[TBL] [Abstract][Full Text] [Related]
5. A model-based approach to predict longitudinal HbA1c, using early phase glucose data from type 2 diabetes mellitus patients after anti-diabetic treatment.
Kjellsson MC; Cosson VF; Mazer NA; Frey N; Karlsson MO
J Clin Pharmacol; 2013 Jun; 53(6):589-600. PubMed ID: 23606523
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Addy C; Tatosian D; Glasgow XS; Gendrano IN; Kauh E; Martucci A; Johnson-Levonas AO; Selverian D; Matthews CZ; Gutierrez M; Wagner JA; Aubrey Stoch S
Clin Ther; 2016 Mar; 38(3):516-30. PubMed ID: 26869191
[TBL] [Abstract][Full Text] [Related]
7. Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.
Zhang X; Schneck K; Bue-Valleskey J; Yeo KP; Heathman M; Sinha V
J Pharmacokinet Pharmacodyn; 2013 Feb; 40(1):53-65. PubMed ID: 23263772
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Piragliatin, a Glucokinase Activator, and Glyburide, a Sulfonylurea, in Type 2 Diabetic Patients.
Zhai S; Georgy A; Liang Z; Zhi J
Clin Pharmacol Drug Dev; 2016 Nov; 5(6):552-556. PubMed ID: 27274007
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.
Stringer F; DeJongh J; Enya K; Koumura E; Danhof M; Kaku K
Diabetes Technol Ther; 2015 Mar; 17(3):215-23. PubMed ID: 25531677
[TBL] [Abstract][Full Text] [Related]
11. Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus.
Li H; Xu J; Fan X
J Pharmacol Sci; 2015 Feb; 127(2):170-80. PubMed ID: 25727954
[TBL] [Abstract][Full Text] [Related]
12. Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study.
Denney WS; Denham DS; Riggs MR; Amin NB
Clin Pharmacol Drug Dev; 2016 Nov; 5(6):517-527. PubMed ID: 27870481
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
[TBL] [Abstract][Full Text] [Related]
14. Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model.
Monte SV; Schentag JJ; Adelman MH; Paladino JA
J Diabetes Sci Technol; 2010 Mar; 4(2):382-90. PubMed ID: 20307400
[TBL] [Abstract][Full Text] [Related]
15. Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.
de Winter W; Dunne A; de Trixhe XW; Devineni D; Hsu CH; Pinheiro J; Polidori D
Br J Clin Pharmacol; 2017 May; 83(5):1072-1081. PubMed ID: 28138980
[TBL] [Abstract][Full Text] [Related]
16. A Model-Informed Approach to Accelerate the Clinical Development of Janagliflozin, an Innovative SGLT2 Inhibitor.
Song L; Wang X; Sun J; Hu X; Li H; Hu P; Liu D
Clin Pharmacokinet; 2023 Mar; 62(3):505-518. PubMed ID: 36802026
[TBL] [Abstract][Full Text] [Related]
17. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
Weng J
J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
[TBL] [Abstract][Full Text] [Related]
18. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection.
Zhu XX; Zhu DL; Li XY; Li YL; Jin XW; Hu TX; Zhao Y; Li YG; Zhao GY; Ren S; Zhang Y; Ding YH; Chen L
Diabetes Obes Metab; 2018 Sep; 20(9):2113-2120. PubMed ID: 29707866
[TBL] [Abstract][Full Text] [Related]
19. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus.
Kiyosue A; Hayashi N; Komori H; Leonsson-Zachrisson M; Johnsson E
Diabetes Obes Metab; 2013 Oct; 15(10):923-30. PubMed ID: 23522182
[TBL] [Abstract][Full Text] [Related]
20. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin.
Wilding JP; Leonsson-Zachrisson M; Wessman C; Johnsson E
Diabetes Obes Metab; 2013 Aug; 15(8):750-9. PubMed ID: 23464532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
